<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03651557</url>
  </required_header>
  <id_info>
    <org_study_id>Neu2000KWL-P02</org_study_id>
    <nct_id>NCT03651557</nct_id>
  </id_info>
  <brief_title>Antioxidant and NMDA Receptor Blocker Wins Anoxic Brain Damage of KorEa OHCA Patients</brief_title>
  <acronym>AWAKE</acronym>
  <official_title>A Phase II, Double-blind, Randomized, Placebo-controlled, Multicenter Trial to Assess the Efficacy and Safety of Neu2000KWL in Patients Who Resuscitated After Out-of-hospital Cardiac Arrest Patient and Receiving Therapeutic Hypothermia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GNT Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Samsung Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Chonnam National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Gangnam Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Kyungpook National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pusan National University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soonchunhyang University Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>GNT Pharma</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims to investigate the efficacy and safety of Neu2000KWL, a neuroprotectant, in
      patients resuscitated from out-of-hospital cardiac arrest and receiving therapeutic
      hypothermia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lack of good neurological recovery is the biggest hurdle in the treatment of out-of-hospital
      cardia arrest. Neu2000KWL, a N-Methyl-D-aspartate (NMDA) receptor antagonist and an
      antioxidant, attenuated cerebral neuronal death and reduced hypoxic injury of brain in
      preclinical studies. Phase I clinical study has revealed that Neu2000KWL is very safe for
      treating human. In current study, the investigators will assess the efficacy of Neu2000KWL to
      compare the neurological biomarker, brain imaging, and clinical outcomes of patients
      successfully resuscitated from out-of-cardiac arrest treated by 3-day infusion of Neu2000KWL
      with patients assigned to placebo arm.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">November 29, 2018</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double Blind (Subject, Caregiver, Investigator)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Verification of difference between of Neuron specific enolase (NSE) value at after 4th infusion of Neu2000KWL.</measure>
    <time_frame>The 3rd day of study (which corresponds to finished 4th infusion of Neu2000KWL).</time_frame>
    <description>Blood concentration of neuron specific enolase (NSE)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Verification of difference between the cumulative of neuron specific enolase (NSE) values at after 6th infusion of Neu2000KWL</measure>
    <time_frame>The 4th day of study (which corresponds to finished 6th infusion of Neu2000KWL).</time_frame>
    <description>Cumulative Blood concentration of neuron specific enolase (NSE)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verification of the difference between groups of Change in NSE values at after the 2nd infusion of Neu2000KWL and after the 6th infusion</measure>
    <time_frame>At the 24 hours and 72 hours after the first infusion of Neu2000KWL.</time_frame>
    <description>The difference of blood neuron specific enolase (NSE) between 24 hour (day 1) and 72 hour (day 3) after the first infusion of Neu2000KWL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verification of difference between each group of NSE values at after 6th infusion after 1st infusion of Neu2000KWL and 24 hours after end of last infusion</measure>
    <time_frame>The 4th and 5th day of study (which corresponds to the timepoint of finished treatment using Neu2000KWL and 24 hour after finished treatment using Neu2000KWL).</time_frame>
    <description>The difference of blood neuron specific enolase (NSE) between day 4 and day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verification of difference between the cerebral infarction at analysis of brain MRI's Apparent Diffusion Coefficient(ADC) images within 48 hours of the last infusion of Neu2000KWL</measure>
    <time_frame>The 5th day of study (which corresponds to 48 hours after finished treatment using Neu2000KWL).</time_frame>
    <description>Blood neuron specific enolase (NSE) at day 5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verification of difference between groups of Neurological function evaluated by cerebral performance category (CPC) and modified Rankin Scale (mRS) at 5 day, 14 day, or discharge within 14 days, and 90 days after 1st infusion of Neu2000KWL.</measure>
    <time_frame>5 day, 14 day, or discharge within 14 days, and 90 days after 1st infusion of Neu2000KWL</time_frame>
    <description>Neurological function evaluated by cerebral performance category (CPC), which ranges 1 to 5 (1: best, 5: worst), and neurological function evaluated by modified Rankin Scale (mRS), which ranges 0 to 6 (0:best, 6: worst)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Verification of difference between groups of Cumulative value of blood S100beta from 6th infusion after 1st infusion of Neu2000KWL.</measure>
    <time_frame>The 4th day of study (which corresponds to finished 6th infusion of Neu2000KWL).</time_frame>
    <description>Cumulative blood concentration of S100beta .</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Serious adverse event</measure>
    <time_frame>90 days</time_frame>
    <description>Safety Outcome Measure
Number of participants with treatment-related adverse events assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0</description>
  </other_outcome>
  <other_outcome>
    <measure>Mortality within 90 days</measure>
    <time_frame>90 days</time_frame>
    <description>Safety Outcome Measure</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Cardiac Arrest</condition>
  <arm_group>
    <arm_group_label>Neu2000KWL high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Neu2000KWL low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neu2000KWL High-dose group</intervention_name>
    <description>1st infusion of 1500mg in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of 750 mg at intervals of 12 hours(Total drug dosage is 5250mg.)</description>
    <arm_group_label>Neu2000KWL high dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neu2000KWL Low-dose group</intervention_name>
    <description>1st infusion of 750mg in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of 500 mg at intervals of 12 hours (Total drug dosage is 3250mg.)</description>
    <arm_group_label>Neu2000KWL low dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1st infusion of the same volume of saline in patients within 4 hours following sudden cardiac arrest onset followed by 5 consecutive infusions of the same volume of saline at intervals of 12 hours</description>
    <arm_group_label>saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 19 Years to 80 Years (Adult)

          2. Out-of-hospital cardiac arrest caused by non-perfusing cardiac rhythm

          3. Successful resuscitation accompanied by ROSC time of more than 20 min

          4. Therapeutic hypothermia is planned or initiated

          5. The first infusion is planned within 4 hours after ROSC

          6. Informed consent is obtained from patient or family member(s)

          7. No concern with previous cardiovascular surgery

        Exclusion Criteria:

          1. Hypersensitivity to aspirin or sulfasalazine

          2. Unwitnessed cardiac arrest

          3. CPR time &gt; 60 min

          4. Therapeutic hypothermia is not planned

          5. Use of extracorporeal membrane oxygenation (ECMO) at initiation of in-hospital
             resuscitation (E-CPR)

          6. Very poor prognosis is expected: patients with (A) non-cardiac or respiratory arrest,
             (B) poor basal neurological status (C) secondary cardiac arrest caused by trauma,
             major bleeding, acute neurologic disease including stroke or tumor, (D) multiorgan
             failure or advanced malignancy

          7. Pregnant or lactating women

          8. Participated in other clinical studies within 90 days before randomization; or
             participating in other clinical trials at present

          9. Intracranial bleeding verified by first brain CT imaging

         10. The investigators consider the patients are not suitable for this trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-Ho Choi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Professor, Department of Emergency Medicine, Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Korea</state>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Bucheon Hospital</name>
      <address>
        <city>Bucheon</city>
        <zip>14584</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>49241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 26, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>March 5, 2019</last_update_submitted>
  <last_update_submitted_qc>March 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 6, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neu2000KWL</keyword>
  <keyword>cerebral performance category</keyword>
  <keyword>out-of-hospital cardiac arrest</keyword>
  <keyword>neuroprotection</keyword>
  <keyword>glutamate</keyword>
  <keyword>N-Methyl-D-aspartate (NMDA) receptor antagonist</keyword>
  <keyword>Anti-oxidant</keyword>
  <keyword>free radical</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Arrest</mesh_term>
    <mesh_term>Out-of-Hospital Cardiac Arrest</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salicylates</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

